EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Multisystem Serositis Following Immunotherapy for Metastatic Melanoma: A Case Report

Shraddha Sriraman, Ricky Dylan Frazer, Helen Winter

Case Reports in Oncology · 07.11.2026

DOI: 10.1159/cro/abzag049 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 07.11.2026. Verfasst von Shraddha Sriraman und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immune checkpoint inhibitors have significantly improved outcomes in metastatic melanoma but are associated with a broad spectrum of immune-related adverse events. Serositis is a rare complication of immunotherapy and may present significant diagnostic and therapeutic challenges, particularly when recurrent or refractory to corticosteroid therapy. Case Presentation We report the case of a 40-year-old man with Stage IV BRAF-mutant metastatic melanoma who developed generalised serositis while receiving maintenance nivolumab following combination ipilimumab and nivolumab therapy. Initial presentation occurred 10 months after commencing nivolumab maintenance and was characterised by generalised oedema, pleural effusions, pericardial effusion, ascites, and bowel wall oedema. Extensive investigation excluded infectious and malignant causes, with pleural fluid cytology repeatedly negative for malignant cells. Symptoms initially improved with high-dose corticosteroids but recurred during steroid tapering despite treatment with mycophenolate mofetil and colchicine. Subsequent treatment with infliximab resulted in marked clinical improvement, allowing successful corticosteroid weaning and sustained symptom control.

Conclusion

To our knowledge, this represents the longest reported follow-up of recurrent immune-mediated multisystem serositis associated with immune checkpoint inhibition and the first report demonstrating successful long-term control with infliximab after failure of corticosteroids, mycophenolate mofetil and colchicine.

Zitieren

APA

Sriraman, S., Frazer, R. D., & Winter, H. (2026). Multisystem Serositis Following Immunotherapy for Metastatic Melanoma: A Case Report. Case Reports in Oncology. https://doi.org/10.1159/cro/abzag049

Vancouver

Sriraman S, Frazer RD, Winter H. Multisystem Serositis Following Immunotherapy for Metastatic Melanoma: A Case Report. Case Reports in Oncology. 2026. doi:10.1159/cro/abzag049

BibTeX
@article{Sriraman2026,
  author = {Sriraman, Shraddha and Frazer, Ricky Dylan and Winter, Helen},
  title = {Multisystem Serositis Following Immunotherapy for Metastatic Melanoma: A Case Report},
  journal = {Case Reports in Oncology},
  year = {2026},
  doi = {10.1159/cro/abzag049}
}
Kostenlos starten →